2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-120179A
    LP-922761 hydrate ≥98.0%
    LP-922761 hydrate is a potent, selective and orally active adapter protein-2 associated kinase 1 (AAK1) inhibitor with IC50s of 4.8 nM and 7.6 nM in enzyme and cell assays, respectively. LP-922761 hydrate also inhibits BMP-2-inducible protein kinase (BIKE) with an IC50 of 24 nM. LP-922761 hydrate shows less activity at cyclin G-associated kinase (GAK), opioid, adrenergic α2 or GABAa receptors.
    LP-922761 hydrate
  • HY-120251A
    Leteprinim potassium 192564-13-9 ≥99.0%
    Leteprinim potassium (AIT-082), a purine analog, is a neuroprotective agent and cognitive enhancer. Leteprinim potassium is a hypoxanthine derivative neurotrophic agent. Leteprinim potassium can induce brain-derived neurotrophic factor (BDNF) mRNA production following spinal cord lesions, and nerve growth factor (NGF) mRNA production in basal forebrain. Leteprinim potassium reduces glutamate toxicity in cultured hippocampal neurons. Leteprinim potassium increases heme-oxygenase 1 and 2 mRNA levels that play role in cellular defense against reactive oxygen species.
    Leteprinim potassium
  • HY-121156A
    Anatibant hydrochloride 209788-45-4 98%
    Anatibant (LF 16-0687; XY-2405) hydrochloride is a selective non-peptide bradykinin B2 receptor antagonist. Anatibant hydrochloride binds to the human, rat and guinea-pig recombinant B2 receptor with Ki values of 0.67 nM, 1.74 nM and 1.37 nM, respectively. Anatibant hydrochloride crosses the blood-brain barrier (BBB). Anatibant hydrochloride can be used in research on brain damage diseases.
    Anatibant hydrochloride
  • HY-121636S
    Resolvin D2-d5 1881277-33-3 ≥99.0%
    Resolvin D2-d5 is the deuterium labeled Resolvin D2. Resolvin D2 is a metabolite of docosahexaenoic acid (DHA), with anti-inflammatory, anti-infective activities. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Resolvin D2 is a remarkably potent inhibitor of TRPV1 (IC50 = 0.1 nM) and TRPA1 (IC50 = 2 nM) in primary sensory neurons.
    Resolvin D2-d5
  • HY-122794A
    Tyrosylleucine TFA 66852-01-5 98.05%
    Tyrosylleucine (Tyr-Leu, YL) TFA, an orally active dipeptide, exhibits a potent antidepressant-like activity.
    Tyrosylleucine TFA
  • HY-123033C
    Nicotinamide riboside malate 2415659-01-5 98.04%
    Nicotinamide riboside malate, an orally active NAD+ precursor, increases NAD+ levels and activates SIRT1 and SIRT3. Nicotinamide riboside malate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities. Nicotinamide riboside malate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease.
    Nicotinamide riboside malate
  • HY-123178S
    Fenpropathrin-d5 ≥98.0%
    Fenpropathrin-d5 is the deuterium labeled Fenpropathrin. Fenpropathrin is a synthetic pyrethroid insecticide in agriculture. Fenpropathrin may induces parkinsonian symptoms progressively.
    Fenpropathrin-d5
  • HY-124283A
    LEI-101 2250025-91-1 ≥99.0%
    LEI-101 is a potent, selective, and orally bioavailable cannabinoid CB2 receptor agonist, with a pEC50 of 8 for hCB2, and a pKi of less than 4 for hERG. LEI-101 is ~100-fold more potent in binding to CB2 receptors than to CB1 receptors.
    LEI-101
  • HY-127029A
    Umbelliprenin 23838-17-7 99.93%
    Umbelliprenin, a prenylated coumarin, is an antioxidant with anticancer, anti-inflammatory and immunomodulatory effects. Umbelliprenin inhibits lipoxygenase managing the inflammation pathways. In inflammatory macrophages, Umbelliprenin suppresses nitric oxide production as well as inducible nitric oxide synthase (NO synthase).
    Umbelliprenin
  • HY-127109A
    Tisolagiline methylsulfate 1894207-45-4 98%
    Tisolagiline methylsulfate (KDS2010) is the selective, reversible and orally active inhibitor for MAO-B with an IC50 of 8 nM. Tisolagiline methylsulfate exhibits neuroprotective and anti-neuroinflammatory activities.
    Tisolagiline methylsulfate
  • HY-12715S1
    Yohimbine-d3 133146-00-6 ≥99.0%
    Yohimbine-d3 is the deuterium labeled Yohimbine (HY-12715).
    Yohimbine-d3
  • HY-12749AS
    Midodrine-d6 hydrochloride 1188265-43-1 99.44%
    Midodrine-d6 (hydrochloride) is deuterium labeled Midodrine, which is a vasopressor/antihypotensive agent.
    Midodrine-d6 hydrochloride
  • HY-128853S
    Taurodeoxycholate-d6 sodium salt 2687960-92-3 99.4%
    Taurodeoxycholate-d6 sodium salt is a bile salt-related anionic detergent. Taurodeoxycholate-d6 sodium salt is formed in the liver by conjugation of deoxycholate with Taurine (HY-B0351). Taurodeoxycholate-d6 sodium salt is used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholate-d6 (TDCA) exhibits anti-inflammatory and neuroprotective effects.
    Taurodeoxycholate-d6 sodium salt
  • HY-129636A
    (E/Z)-CLH304a 797-17-1 98%
    (E/Z)-CLH304a (GABAB receptor antagonist 1) is a mixture of (E)-CLH304a and (Z)-CLH304a. (E)-CLH304a (CLH304a; HY-129636) is a specific and noncompetitive GABAB receptor negative allosteric modulator (NAM). CLH304a inhibits Baclofen (HY-B0007)-induced ERK1/2 phosphorylation in HEK293 cells overexpressing GABAB receptors.
    (E/Z)-CLH304a
  • HY-132417S
    (rac)-N,O-Didesmethyl Tramadol-d3 1261398-22-4 98%
    (rac)-N,O-Didesmethyl Tramadol-d3 is a deuterium labeled (rac)-N,O-Didesmethyl Tramadol. (rac)-N,O-Didesmethyl Tramadol is the main metabolite of Tramadol.
    (rac)-N,O-Didesmethyl Tramadol-d3
  • HY-133111S
    3-Hydroxy agomelatine-d3 1079774-23-4 99.92%
    3-Hydroxy agomelatine-d3 is a deuterium labeled 3-Hydroxy agomelatine. 3-Hydroxy agomelatine is a 5-HT2C receptor antagonist with an IC50 of 3.2 μM and a Ki of 1.8 μM.
    3-Hydroxy agomelatine-d3
  • HY-133113S
    7-Desmethyl-agomelatine-d3 2749427-92-5 ≥99.0%
    7-Desmethyl-agomelatine-d3 is a deuterium labeled 7-Desmethyl-agomelatine. 7-Desmethyl-agomelatine is a metabolite of Agomelatine.
    7-Desmethyl-agomelatine-d3
  • HY-133116S
    4-Hydroxyatomoxetine-d3 1217686-14-0 98.89%
    4-Hydroxyatomoxetine-d3 is a deuterium labeled 4-Hydroxyatomoxetine. 4-Hydroxyatomoxetine is an active metabolite of Atomoxetine (Tomoxetine). 4-Hydroxyatomoxetine is metabolized by the enzyme cytochrome P450 2D6 (CYP2D6). Atomoxetine is a potent and selective noradrenal in re-uptake inhibitor.
    4-Hydroxyatomoxetine-d3
  • HY-134189A
    EST73502 monohydrochloride 2535970-65-9 99.58%
    EST73502 monohydrochloride is a selective, orally active and blood-brain barrier (BBB) penetrant dual μ-opioid receptor (MOR) agonist and σ1 receptor (σ1R) antagonist, with Kis of 64 nM and 118 nM for MOR and σ1R, respectively. EST73502 monohydrochloride has antinociceptive activity.
    EST73502 monohydrochloride
  • HY-134269A
    8-Br-7-CH-cADPR disodium 98.74%
    8-Br-7-CH-cADPR disodium (7-Deaza-8-bromo-cADPR) is a potent cADPR antagonist. 8-Br-7-CH-cADPR disodium shows partial inhibition of calcium elevation caused by sTIR dimerization. 8-Br-7-CH-cADPR disodium significantly decreases Paclitaxel (HY-B0015)-induced axon degeneration.
    8-Br-7-CH-cADPR disodium
Cat. No. Product Name / Synonyms Application Reactivity